Real-world evidence (RWE) refers to information on health care that comes from real-world settings, such as electronic health records (EHRs), insurance claims, product and disease registries, patient-generated data, and emerging sources like wearables and social media.
RWE is becoming increasingly important in the management of rare diseases like Addison’s disease, which is characterized by insufficient hormone production from the adrenal glands. Here are some benefits RWE can provide:
[1] Improved Understanding of Natural Disease Progression: Due to the low prevalence of rare diseases, our understanding of them often lacks detail. Real-world data can help fill these knowledge gaps by offering insights into the disease’s natural history and progression.
[2] Efficacy and Safety of Treatments: Clinical trials are the gold standard for assessing the efficacy and safety of new treatments, but they may not represent the broader patient population due to their strict inclusion and exclusion criteria. RWE, being derived from a diverse population, can provide insight into how a treatment works in a broader range of patients.
[3] Patient-focused Drug Development: With RWE, researchers can understand the burden of disease and the benefits patients value most, which can guide patient-focused drug development.
[4] Health Economics and Outcomes Research (HEOR): RWE can provide critical data for health economic evaluations, cost-effectiveness studies, and budget impact analyses.
[5] Early Identification and Diagnosis: Since many rare diseases often go undiagnosed due to their rarity and a lack of awareness among healthcare providers, RWE can help in early identification and diagnosis by revealing patterns or correlations that might not be apparent in smaller datasets.
[6] Post-marketing Surveillance: After a drug has been approved, RWE can be used to monitor its long-term effectiveness and side effects in a larger population.
[7] Guiding Clinical Practice: By understanding how treatments work in the real world, doctors can be better informed about the likely benefits and risks for individual patients, thus guiding personalized treatment.
However, it’s important to note that while RWE provides numerous benefits, it also comes with challenges, including data quality and integrity, privacy and security concerns, and the need for sophisticated analytical methods to derive meaningful conclusions from complex and heterogenous datasets.
Share this story...
Real World Evidence (RWE) 101 – Data Tokenization
RWE 101 - 4 Potential Uses for Improving Drug Development Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as [...]
Real World Evidence (RWE) 101 – Primary Data versus Secondary Data
RWE 101 - Primary Data versus Secondary Data Primary data and secondary data are two types of data used in research. The main difference between the two [...]
RWE 101 – Secondary Use of Existing Data
RWE 101 - Secondary Use of Existing Data Secondary use of existing data refers to the practice of analyzing data that was collected for a different purpose [...]
RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?
RWE 101 - Why is there so much excitement about the use of AI in the context of real world evidence? The use of Artificial Intelligence (AI) [...]
RWE 101 – What is the Difference Between an IRB and a REC?
RWE 101 - What is the Difference Between an IRB and a REC? An Institutional Review Board (IRB) and a Research Ethics Committee (REC) are two different [...]
RWE 101 – Do I Need IRB Approval for My Observational Study?
RWE 101 - Do I Need IRB Approval for My Observational Study? In general, observational studies that involve human subjects require Institutional Review Board (IRB) approval to [...]







